Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Moleculin Biotech, Inc. (NASDAQ: MBRX) announced its participation in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 12:40 PM ET. Jonathan P. Foster, the Chief Financial Officer, will present a live video webcast, accessible on the Company's website. This event will also allow one-on-one meetings with registered investors. Moleculin focuses on developing treatments for hard-to-treat tumors and viruses, highlighted by its lead program Annamycin for acute myeloid leukemia and soft tissue sarcoma. The Company is also advancing several other oncology and antiviral candidates.

News Market Reaction

-6.23%

1 alert

-6.23% News Effect

On the day this news was published, MBRX declined 6.23%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Presentation with live video webcast on Tuesday, March 14^th at 12:40 PM ET

HOUSTON, March 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that Jonathan P. Foster, Chief Financial Officer of Moleculin, will present at the virtual Oppenheimer 33^rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 12:40 PM ET.

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (moleculin.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-301769678.html

SOURCE Moleculin Biotech, Inc.

FAQ

When is Moleculin Biotech's presentation at the Oppenheimer 33rd Annual Healthcare Conference?

Moleculin Biotech will present on March 14, 2023, at 12:40 PM ET.

Who will represent Moleculin Biotech at the conference?

Jonathan P. Foster, the Chief Financial Officer, will represent the company.

How can I access the live video webcast of Moleculin's presentation?

The live video webcast can be accessed on the Investors section of Moleculin's website.

What is Moleculin Biotech's lead program?

The lead program is Annamycin, designed for treating acute myeloid leukemia and soft tissue sarcoma.

What other treatments is Moleculin Biotech developing?

Moleculin is developing additional drugs targeting various cancers and viral infections, including WP1066 and WP1122.